Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

Clinical trial NCT07432100 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07432100
Sponsor: Mingfeng Zhao
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Chimeric Antigen Receptor T-cell Universal CLL1 CAR-T

Start date: 2026-02-01
Primary completion: 2028-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.